"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B2,US 8014544 B2,017-945-478-414-326,2011-09-06,2011,US 89912307 A,2007-09-04,US 89912307 A,2007-09-04,Computer installed stereo PA amplifier card,"The present invention is a stereo PA amplifier that is mounted inside a desktop computer. It is powered by the computer's 12-volt power supply and receives its input via a stereo mini cable from the computer's audio line out. Standard 8-ohm, non-powered speakers are then hooked up directly to the board via its speaker connector board. The volume of the present invention is adjusted by the computer's volume controls. The device eliminates the need for an external stereo amp and external mixer, which thereby reduces the installation time, cost, interconnecting cables, and the space needed for the overall computer system, while at the same time providing quality sound.",FREELS STEPHEN;;CALDERON RICK,FREELS STEPHEN;;CALDERON RICK,,https://lens.org/017-945-478-414-326,Granted Patent,yes,4,4,2,2,0,H03F3/185;;H03F3/45475;;H03F3/68;;H03F2200/03;;H04R27/00;;G06F3/162;;H03F3/185;;H03F2200/03;;H03F3/45475;;H03F3/68;;H04R27/00;;G06F3/162,H03F99/00;;H04R27/00,381/120;;381/122;;381/82,0,0,,,,INACTIVE
2,US,A1,US 2009/0060221 A1,167-021-339-421-381,2009-03-05,2009,US 89912307 A,2007-09-04,US 89912307 A,2007-09-04,Computer installed stereo PA amplifier card,"The present invention is a stereo PA amplifier that is mounted inside a desktop computer. It is powered by the computer's 12-volt power supply and receives its input via a stereo mini cable from the computer's audio line out. Standard 8-ohm, non-powered speakers are then hooked up directly to the board via its speaker connector board. The volume of the present invention is adjusted by the computer's volume controls. The device eliminates the need for an external stereo amp and external mixer, which thereby reduces the installation time, cost, interconnecting cables, and the space needed for the overall computer system, while at the same time providing quality sound.",FREELS STEPHEN;;CALDERON RICK,FREELS STEPHEN;;CALDERON RICK,,https://lens.org/167-021-339-421-381,Patent Application,yes,4,3,2,2,0,H03F3/185;;H03F3/45475;;H03F3/68;;H03F2200/03;;H04R27/00;;G06F3/162;;H03F3/185;;H03F2200/03;;H03F3/45475;;H03F3/68;;H04R27/00;;G06F3/162,H04R27/00,381/82,0,0,,,,INACTIVE
3,US,A,US 4793370 A,079-124-268-572-087,1988-12-27,1988,US 5690587 A,1987-06-03,US 5690587 A,1987-06-03,Crutch cast support,"A crutch cast support or crutch leg support is provided by a loop of flexible material attached to a crutch at a location of the crutch that is closer to a shoulder support of the crutch than to a hand hold of the crutch, the loop of flexible material hanging loosely from a mounting mechanism that mounts the loop to the crutch. Preferably, the mounting mechanism provides three degrees of freedom where the loop is mounted to the crutch to enhance swinging motion of the loop in a walking direction with respect to the crutch, in a direction transverse to the walking direction, and in rotation about an axis disposed in a longitudinal direction of the crutch. The loop of flexible material is provided by a strap, the length of which is adjustable, so that a leg of a user may be supported at a wide variety of places including the area of the knee, a location closer to the ankle than to the knee, and from below the foot.",PEREZ IGNACIO;;CALDERON STEPHEN M,PEREZ IGNACIO;;CALDERON STEPHEN M,,https://lens.org/079-124-268-572-087,Granted Patent,yes,4,26,1,1,0,A61H3/02;;A61H3/02;;A61H2003/005;;A61H2003/005,A61H3/00;;A61H3/02,135/69;;135/65;;135/68,0,0,,,,EXPIRED
4,US,B2,US 10576235 B2,187-255-351-752-009,2020-03-03,2020,US 201715598510 A,2017-05-18,US 201715598510 A,2017-05-18,Management of a therapeutic oxygen delivery system,"Described embodiments include a therapeutic oxygen supply apparatus. The apparatus includes at least two components, including an intake manifold component configured to receive concentrated oxygen, a compressor component configured to compress concentrated oxygen, an oxygen tank component configured to store concentrated oxygen, a patient manifold component configured to supply concentrated oxygen, or a control structure component configured to route a flow of concentrated oxygen. A sensor circuit acquires data indicative of a respective operational state of the at least two components. A rule-based engine selects a next operational state of a component in response to (i) the acquired data indicative of the respective operational states of the at least two components and (ii) a rule database having at least one rule responsive to an objective providing a therapeutic flow of oxygen to the patient. A configuration manager circuit generates a control signal implementing the selected next operational state.",TOKITAE LLC,BURKOT STEPHEN THOMAS GRAVES;;CALDERON RYAN;;KUIPER MARK K;;LIEBERMAN DANIEL HOWARD;;NG CHIN HEI,TOKITAE LLC (2017-05-19),https://lens.org/187-255-351-752-009,Granted Patent,yes,24,0,4,4,0,A61M16/101;;A61M16/101;;A61M16/0063;;A61M16/0063;;A61M2016/1025;;A61M2016/1025;;A61M2202/0208;;A61M2202/0208;;A61M2205/16;;A61M2205/3334;;A61M2205/3334;;A61M2205/50;;A61M2205/50;;A61M2205/84;;A61M2205/84;;G16H20/40;;G16H40/60,A61M16/10;;A61M16/00;;G16H20/40;;G16H40/60,,1,0,,,"PCT International Search Report; International App. No. PCT/US2018/032243; dated Sep. 21, 2018; pp. 1-3.",ACTIVE
5,TW,A,TW 201900233 A,030-555-068-353-820,2019-01-01,2019,TW 107116373 A,2018-05-15,US 201715598510 A,2017-05-18,Management of a therapeutic oxygen delivery system,"Described embodiments include a therapeutic oxygen supply apparatus. The apparatus includes at least two components, including an intake manifold component configured to receive concentrated oxygen, a compressor component configured to compress concentrated oxygen, an oxygen tank component configured to store concentrated oxygen, a patient manifold component configured to supply concentrated oxygen, or a control structure component configured to route a flow of concentrated oxygen. A sensor circuit acquires data indicative of a respective operational state of the at least two components. A rule-based engine selects a next operational state of a component in response to (i) the acquired data indicative of the respective operational states of the at least two components and (ii) a rule database having at least one rule responsive to an objective providing a therapeutic flow of oxygen to the patient. A configuration manager circuit generates a control signal implementing the selected next operational state.",TOKITAE LLC,BURKOT STEPHEN THOMAS GRAVES;;CALDERON RYAN;;KUIPER MARK K;;LIEBERMAN DANIEL HOWARD;;NG CHIN HEI,,https://lens.org/030-555-068-353-820,Patent of Addition,no,0,0,4,4,0,A61M16/101;;A61M16/101;;A61M16/0063;;A61M16/0063;;A61M2016/1025;;A61M2016/1025;;A61M2202/0208;;A61M2202/0208;;A61M2205/16;;A61M2205/3334;;A61M2205/3334;;A61M2205/50;;A61M2205/50;;A61M2205/84;;A61M2205/84;;G16H20/40;;G16H40/60,A61M16/00,,0,0,,,,PENDING
6,WO,A1,WO 2018/213118 A1,019-239-889-378-053,2018-11-22,2018,US 2018/0032243 W,2018-05-11,US 201715598510 A,2017-05-18,MANAGEMENT OF A THERAPEUTIC OXYGEN DELIVERY SYSTEM,"Described embodiments include a therapeutic oxygen supply apparatus. The apparatus includes at least two components, including an intake manifold component configured to receive concentrated oxygen, a compressor component configured to compress concentrated oxygen, an oxygen tank component configured to store concentrated oxygen, a patient manifold component configured to supply concentrated oxygen, or a control structure component configured to route a flow of concentrated oxygen. A sensor circuit acquires data indicative of a respective operational state of the at least two components. A rule-based engine selects a next operational state of a component in response to (i) the acquired data indicative of the respective operational states of the at least two components and (ii) a rule database having at least one rule responsive to an objective providing a therapeutic flow of oxygen to the patient. A configuration manager circuit generates a control signal implementing the selected next operational state.",TOKITAE LLC,BURKOT STEPHEN THOMAS GRAVES;;CALDERON RYAN;;KUIPER MARK K;;LIEBERMAN DANIEL HOWARD;;NG CHIN HEI,,https://lens.org/019-239-889-378-053,Patent Application,yes,5,0,4,4,0,A61M16/101;;A61M16/101;;A61M16/0063;;A61M16/0063;;A61M2016/1025;;A61M2016/1025;;A61M2202/0208;;A61M2202/0208;;A61M2205/16;;A61M2205/3334;;A61M2205/3334;;A61M2205/50;;A61M2205/50;;A61M2205/84;;A61M2205/84;;G16H20/40;;G16H40/60,A61M16/10;;A61M16/00,,0,0,,,,PENDING
7,US,A1,US 2018/0333554 A1,097-642-038-388-295,2018-11-22,2018,US 201715598510 A,2017-05-18,US 201715598510 A,2017-05-18,MANAGEMENT OF A THERAPEUTIC OXYGEN DELIVERY SYSTEM,"Described embodiments include a therapeutic oxygen supply apparatus. The apparatus includes at least two components, including an intake manifold component configured to receive concentrated oxygen, a compressor component configured to compress concentrated oxygen, an oxygen tank component configured to store concentrated oxygen, a patient manifold component configured to supply concentrated oxygen, or a control structure component configured to route a flow of concentrated oxygen. A sensor circuit acquires data indicative of a respective operational state of the at least two components. A rule-based engine selects a next operational state of a component in response to (i) the acquired data indicative of the respective operational states of the at least two components and (ii) a rule database having at least one rule responsive to an objective providing a therapeutic flow of oxygen to the patient. A configuration manager circuit generates a control signal implementing the selected next operational state.",TOKITAE LLC,BURKOT STEPHEN THOMAS GRAVES;;CALDERON RYAN;;KUIPER MARK K;;LIEBERMAN DANIEL HOWARD;;NG CHIN HEI,TOKITAE LLC (2017-05-19),https://lens.org/097-642-038-388-295,Patent Application,yes,2,2,4,4,0,A61M16/101;;A61M16/101;;A61M16/0063;;A61M16/0063;;A61M2016/1025;;A61M2016/1025;;A61M2202/0208;;A61M2202/0208;;A61M2205/16;;A61M2205/3334;;A61M2205/3334;;A61M2205/50;;A61M2205/50;;A61M2205/84;;A61M2205/84;;G16H20/40;;G16H40/60,A61M16/10;;A61M16/00,,0,0,,,,ACTIVE
8,ES,T3,ES 2295191 T3,029-030-234-611-219,2008-04-16,2008,ES 01959230 T,2001-07-25,US 22124200 P,2000-07-27,POLIPEPTIDOS DE GSK3.,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G,,https://lens.org/029-030-234-611-219,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
9,WO,A1,WO 2023/278921 A1,114-270-638-325-597,2023-01-05,2023,US 2022/0072685 W,2022-06-01,US 202163217690 P;;US 202217716605 A,2021-07-01,SYNERGISTIC ZN/PHENOLIC SOLVENT FORMULATIONS FOR SANITIZATION AND ODOR CONTROL IN LAUNDRY,"Treatment compositions for use in laundry capable of providing sanitization through the wash e.g., for use with a detergent, where the compositions include an inorganic zinc salt potentiated by a phenolic solvent, to provide sanitization. The compositions can include an inorganic zinc salt, and a phenolic solvent, e.g., at an acidic pH (e.g., 2 to 5, or 3.5 to 4.5). The composition can include an anionic surfactant (e.g., alkyl sulfates, alkyl ether sulfates, etc.) and/or a nonionic surfactant (e.g., an alkyl polyglucoside). The composition may be free of alkoxylated nonionic surfactants which are not stable in the present compositions, which have high ionic strength (e.g., due to ~3% of the zinc salt included in the formula). The composition may be free of various other components that would not be stable in such high ionic strength conditions, or otherwise interfere with stability and efficacy of the sanitizing and/or disinfecting laundry composition.",CLOROX CO,FALK NANCY A;;GROSS STEPHEN F;;THAMANNA SHAKERA;;FRAUSTO FANNY;;CAPRACOTTA MICHAEL D;;PENA CALDERON DENNYS D,,https://lens.org/114-270-638-325-597,Patent Application,yes,3,0,2,2,0,C11D3/48;;C11D3/046;;C11D3/2068;;C11D3/24;;C11D3/2034;;C11D3/042;;C11D1/02;;C11D2111/12;;C11D3/122;;C11D3/0047;;C11D3/43,A61K8/27;;A61Q17/00;;C11D1/83;;C11D17/00;;D21H21/36,,0,0,,,,PENDING
10,US,A1,US 2023/0002703 A1,091-085-587-337-274,2023-01-05,2023,US 202217716605 A,2022-04-08,US 202217716605 A;;US 202163217690 P,2021-07-01,SYNERGISTIC Zn/PHENOLIC SOLVENT FORMULATIONS FOR SANITIZATION AND ODOR CONTROL IN LAUNDRY,"Treatment compositions for use in laundry capable of providing sanitization through the wash e.g., for use with a detergent, where the compositions include an inorganic zinc salt potentiated by a phenolic solvent, to provide sanitization. The compositions can include an inorganic zinc salt, and a phenolic solvent, e.g., at an acidic pH (e.g., 2 to 5, or 3.5 to 4.5). The composition can include an anionic surfactant (e.g., alkyl sulfates, alkyl ether sulfates, etc.) and/or a nonionic surfactant (e.g., an alkyl polyglucoside). The composition may be free of alkoxylated nonionic surfactants which are not stable in the present compositions, which have high ionic strength (e.g., due to ˜3% of the zinc salt included in the formula). The composition may be free of various other components that would not be stable in such high ionic strength conditions, or otherwise interfere with stability and efficacy of the sanitizing and/or disinfecting laundry composition.",CLOROX CO,FALK NANCY A;;GROSS STEPHEN F;;THAMANNA SHAKERA;;FRAUSTO FANNY;;CAPRACOTTA MICHAEL D;;PENA CALDERON DENNYS D,THE CLOROX COMPANY (2021-07-01);;BASF CORPORATION (2021-08-09),https://lens.org/091-085-587-337-274,Patent Application,yes,0,0,2,2,0,C11D3/48;;C11D3/046;;C11D3/2068;;C11D3/24;;C11D3/2034;;C11D3/042;;C11D1/02;;C11D2111/12;;C11D3/122;;C11D3/0047;;C11D3/43,C11D3/12;;C11D3/00;;C11D3/43,,0,0,,,,PENDING
11,US,A1,US 2006/0088932 A1,087-468-788-280-757,2006-04-27,2006,US 73381603 A,2003-12-10,US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,CHIRON CORPORATION (2001-01-04);;NOVARTIS VACCINES AND DIAGNOSTICS INC (2001-01-04),https://lens.org/087-468-788-280-757,Patent Application,yes,5,0,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;C12N15/09;;A61K38/00;;C12P21/06;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07H21/04;;C12N9/12,435/320.1;;435/194;;435/69.1;;435/325;;536/23.2,0,0,,,,EXPIRED
12,US,B2,US 6465231 B2,150-584-307-082-700,2002-10-15,2002,US 91610901 A,2001-07-25,US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"
    The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3 and GSK3 polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation. 
",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/150-584-307-082-700,Granted Patent,yes,2,17,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,435/194;;435/15;;530/350;;536/23.2,13,11,165-332-800-449-637;;099-328-331-518-64X;;077-755-206-358-518;;136-172-365-845-608;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;120-185-171-572-797;;051-092-210-790-698;;102-583-874-731-812;;157-895-621-716-196,07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;10.1016/0014-5793(95)00434-b;;7774712;;7704571;;10.1016/s0960-9822(00)00246-3;;10.1016/0968-0004(93)90011-b;;8108862;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10364240;;10.1074/jbc.274.25.17934;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1016/0968-0004(91)90071-3;;1652801;;10.1107/s0021889891004430,"Stambolic et al., Swiss-Prot accession No. P49841, Oct. 1, 1996.*;;US 6,057,286, 5/2000, Harrison et al. (withdrawn);;Cross et al., ""The inhibition of glycogen synthase kinase-3 by insulin of insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf,"" Biochemical Journal 303(Part 1):21-26, Oct. 1, 1994.;;Latimer et al., ""Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau,"" FEBS Letters 356(1):42-46, May 22, 1995.;;Lovestone et al., ""Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells,"" Current Biology 4(12):1077-1086, Dec. 1, 1994.;;Mandelkow and Mandelkow ""Tau as a marker for Alzheimer's disease,"" TIBS 18(12):480-483, Dec. 1993.;;Mulot et al., ""PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be mimicked by in vitro phosphorylation of human brain tau by glycogen synthase kinase 3-beta,"" FEBS Letters 349(3):359-364, Aug. 8, 1994.;;Peifer et al., ""Phosphorylation of the Drosophila adherens junction protein Armadillo: roles for wingless signal and zeste-white 3 kinase,"" Developmental Biology 166(2):543-556, Dec. 1994.;;Saito et al., ""The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells,"" Biochemical Journal 303(Part 1):27-31 Oct. 1, 1994.;;Summers et al., ""The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism,"" Journal of Biological Chemistry 274(25):17934-17940, Jun. 18, 1999.;;Welsh and Proud, ""Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B,"" Biochemical Journal 294(Part 3):625-629, Aug. 15, 1993.;;Woodgett, ""A common denominator linking glycogen metabolism, nuclear oncogenes and development,"" TIBS 16(5):177-181, May 1991.;;Jancarik and Kim, ""Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins,"" J. of Applied Crystallography 24(4):409-411, 1991.",EXPIRED
13,DE,T2,DE 60131550 T2,061-305-373-290-590,2008-10-23,2008,DE 60131550 T,2001-07-25,US 22124200 P;;US 0123539 W,2000-07-27,GSK3-POLYPEPTIDE,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/061-305-373-290-590,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
14,US,A1,US 2008/0182313 A1,061-697-785-431-738,2008-07-31,2008,US 7454308 A,2008-03-03,US 7454308 A;;US 70472407 A;;US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK 3 polypeptides capable of crystallization, including GSK 3 α and GSK 3 β polypeptides, and use of these polypeptides to identify and optimize GSK 3 inhibitors. Also provided are GSK 3 polypeptides having at least one substituted amino acid that differs from wild-type GSK 3 , wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK 3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES AND DIAGONST,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/061-697-785-431-738,Patent Application,yes,2,0,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;A61K35/76;;C12N15/09;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07H21/04;;C12N15/00,435/194;;536/23.2;;435/320.1,0,0,,,,EXPIRED
15,US,A1,US 2002/0082408 A1,081-010-646-470-069,2002-06-27,2002,US 91610901 A,2001-07-25,US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"
    The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK 3 and GSK 3 polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation. 
",HARRISON STEPHEN D.;;HALL JOHN A.;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y.;;COIT DORIS G.;;NGUYEN STEVE H.;;MEDINA-SELBY ANGELICA,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/081-010-646-470-069,Patent Application,yes,0,1,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;C12N15/09;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,536/23.2;;435/194;;435/325;;435/320.1;;435/69.1,0,0,,,,EXPIRED
16,US,A1,US 2007/0249004 A1,095-047-921-261-358,2007-10-25,2007,US 70472407 A,2007-02-08,US 70472407 A;;US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/095-047-921-261-358,Patent Application,yes,1,0,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;G01N33/53;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,435/7.92,0,0,,,,EXPIRED
17,US,A1,US 2005/0048511 A1,146-120-484-673-296,2005-03-03,2005,US 68946103 A,2003-10-20,US 68946103 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,NOVARTIS VACCINES AND DIAGNOSTICS INC (2001-01-04),https://lens.org/146-120-484-673-296,Patent Application,yes,2,4,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;A61K38/00;;A61K48/00;;C12N15/09;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,435/6;;435/69.1;;435/194;;435/320.1;;435/325;;536/23.2,0,0,,,,EXPIRED
18,EP,A1,EP 1914305 A1,155-726-152-422-426,2008-04-23,2008,EP 07022387 A,2001-07-25,EP 01959230 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/155-726-152-422-426,Patent Application,yes,3,0,29,29,10,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,18,14,026-074-902-787-187;;038-819-987-457-345;;102-583-874-731-812;;120-185-171-572-797;;026-432-344-796-392;;051-092-210-790-698;;165-332-800-449-637;;034-002-594-044-070;;136-172-365-845-608;;067-347-783-117-655;;099-328-331-518-64X;;102-583-874-731-812;;048-165-542-714-807;;157-895-621-716-196,2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x;;pmc1132210;;8424800;;10.1042/bj2890593;;10.1016/0968-0004(91)90071-3;;1652801;;10364240;;10.1074/jbc.274.25.17934;;10.1042/bj3030027;;pmc1137551;;7945252;;8397507;;pmc1134506;;10.1042/bj2940625;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7529201;;10.1006/dbio.1994.1336;;10.1016/0968-0004(93)90011-b;;8108862;;8050597;;10.1016/0014-5793(94)00702-0;;10.1016/0014-5793(95)00434-b;;7774712;;10.1016/0968-0004(91)90071-3;;1652801;;2164470;;pmc552268;;10.1002/j.1460-2075.1990.tb07419.x;;10.1107/s0021889891004430,"DATABASE EMBL [online] 1 October 1996 (1996-10-01), STRAUSBERG: ""KG3B_HUMAN (human GSK beta sequence)"", XP002209722, retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?-E+[SW Database accession no. P49841;;DATABASE EMBL [online] 1 November 1996 (1996-11-01), DOMINGUEZ ET AL: ""GSK-beta Xenopus"", XP002209723, Database accession no. Q91627;;DATABASE EMBL [online] 1 October 1996 (1996-10-01), HE: ""KG3A_HUMAN (human GSK alpha)"", XP002209724, Database accession no. P49840;;RANTY B ET AL: ""Truncation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Rhodospirillum rubrum affects the holoenzyme assembly and activity."", THE EMBO JOURNAL. ENGLAND MAY 1990, vol. 9, no. 5, May 1990 (1990-05-01), pages 1365 - 1373, XP001096047, ISSN: 0261-4189;;VAN DER LINDEN M P ET AL: ""Domain organization of penicillin-binding protein 5 from Escherichia coli analysed by C-terminal truncation."", THE BIOCHEMICAL JOURNAL. ENGLAND 15 JAN 1993, vol. 289 ( Pt 2), 15 January 1993 (1993-01-15), pages 593 - 598, XP002209721, ISSN: 0264-6021;;WOODGETT, TRENDS BIOCHEM SCI., vol. 16, 1991, pages 177 - 181;;SUMMERS ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 17934 - 17940;;SAITO ET AL., BIOCHEM. J., vol. 303, 1994, pages 27 - 31;;WELSH ET AL., BIOCHEM. J., vol. 294, 1993, pages 625 - 629;;CROSS, BIOCHEM. J., vol. 303, 1994, pages 21 - 26;;PEIFER ET AL., DEVELOP. BIOL., vol. 166, 1994, pages 543 - 56;;MANDELKOW; MANDELKOW, TRENDS IN BIOCHEM. SCI., vol. 18, 1993, pages 480 - 83;;MULOT ET AL., FEBS LETT, vol. 349, 1994, pages 359 - 64;;LOVESTONE ET AL., CURR. BIOL., vol. 4, 1995, pages 1077 - 86;;LATIMER ET AL., FEBS LETT, vol. 365, 1995, pages 42 - 6;;WOODGETT ET AL., TRENDS BIOCHEM SCI, vol. 16, 1991, pages 177 - 181;;WOODGETT, EMBO J., vol. 9, no. 8, 1990, pages 2431 - 2438;;JANCARIK, J. ET AL., J. APPL. CRYST., vol. 24, 1991, pages 409 - 411",EXPIRED
19,US,B2,US 7195886 B2,012-954-734-623-470,2007-03-27,2007,US 73381603 A,2003-12-10,US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,CHIRON CORPORATION (2001-01-04);;NOVARTIS VACCINES AND DIAGNOSTICS INC (2001-01-04),https://lens.org/012-954-734-623-470,Granted Patent,yes,2,1,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;C12Q1/48;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07K14/00;;C12N5/02;;C12N5/06;;C12N9/12;;C12N15/00;;C12P21/06;;C12P21/08;;G01N33/00;;G01N33/53;;G01N33/563,435/15;;435/69.1;;435/194;;435/325;;435/252.3;;435/320.1;;435/7.1;;435/365;;435/6;;435/7.6;;435/7.8;;435/7.92;;436/86;;436/512;;530/350;;530/388.1;;536/23.2;;536/23.5,20,14,067-021-469-850-816;;120-185-171-572-797;;099-328-331-518-64X;;165-332-800-449-637;;077-755-206-358-518;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;136-172-365-845-608;;038-819-987-457-345;;051-092-210-790-698;;157-895-621-716-196;;102-583-874-731-812;;026-074-902-787-187,11738041;;10.1016/s0969-2126(01)00679-7;;10364240;;10.1074/jbc.274.25.17934;;10.1016/0014-5793(95)00434-b;;7774712;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7704571;;10.1016/s0960-9822(00)00246-3;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10.1016/0968-0004(93)90011-b;;8108862;;pmc1132210;;8424800;;10.1042/bj2890593;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1107/s0021889891004430;;10.1016/0968-0004(91)90071-3;;1652801;;2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x,"Bax et al., Structure 9:1143-1152, Dec. 2001.;;US 6,057,286, 05/2000, Colvin et al. (withdrawn);;Summers et al., The Role of Glycogen Synthase Kinase 3beta in Insulin-Stimulated Glucose Metabolism, Journal of Biological Chemistry, 274(25):17934-17940, 1999.;;Accession No. AAA84444.1, 1996, Database GenBank, Dominguez et al.;;Database EMBL Entry, Accession No. P49840, 1996, He et al.;;Database EMBL Entry, Accession No. P49841, 1996, Stambolic et al.;;Database EMBL Entry, Accession No. Q91627, 1996, Dominguez et al.;;Database EMBL Entry, Accession No. U31862, 1995, Dominguez et al.;;Latimer et al., Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosporylation of Transfected Tau, FEBS Letters, 365(1):42-46, 1995.;;Cross et al., The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activiated Protein Kinase Pathway in L6 Cells Between Ras and Raf, Biochemical Journal, 303(Part 1):21-26, 1994.;;Lovestone et al., Alzheimer's Disease-Like Physphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells, Current Biology, 4(12):1077-1086, 1994.;;Mulot et al., PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3beta, FEBS Letters, 349(3):359-364, 1994.;;Peifer et al., Phosphorylation of the Drosophilia Adherens Junction Protein Armadillo: Roles for Wingless Signals and Zeste-White 3 Kinase, Developmental Biology, 166(2):543-556, 1994.;;Saito et al., The Mechanism by Which Epidermal Growth Factor Inhibits Glycogen Synthase Kinase 3 in A431 Cells, Biochemical Journal, 303(Part 1):27-31, 1994.;;Mandelkow et al., Tau as a Marker for Alzheimer's Disease, TIBS, 18(12):480-483, 1993.;;Van Der Linden et al., Domain Organization of Penicillin-Binding Protein 5 from Escherichia coli Analysed by C-Terminal Truncation, Biochemical Journal, 289(Part 2):593-598, 1993.;;Welsh et al., Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor eIF-2B, Biochemical Journal, 294(Part 3):625-629, 1993.;;Jancarik et al., Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins, J. of Applied Crystallography, 24(4):409-411, 1991.;;Woodgett, A Common Denominator Linking Glycogen Metabolism, Nuclear Oncogenes and Development, TIBS, 16(5):177-181, 1991.;;Ranty et al., Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Holoenzyme Assembly and Activity, EMBO Journal, 9:1365-1373, 1990.",EXPIRED
20,DE,D1,DE 60131550 D1,102-636-278-582-669,2008-01-03,2008,DE 60131550 T,2001-07-25,US 22124200 P;;US 0123539 W,2000-07-27,GSK3-POLYPEPTIDE,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/102-636-278-582-669,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
21,US,B2,US 7135321 B2,036-879-478-722-595,2006-11-14,2006,US 68946103 A,2003-10-20,US 68946103 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,NOVARTIS VACCINES AND DIAGNOSTICS INC (2001-01-04),https://lens.org/036-879-478-722-595,Granted Patent,yes,2,1,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;C12N9/12;;A61K38/00;;C12N15/09;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07H21/04;;C12N1/00;;C12N5/00;;C12N15/54;;C12N15/70;;C12P21/06;;C12Q1/48,435/194;;435/15;;435/320.1;;435/69.1;;435/252.3;;435/325;;536/23.1;;536/23.2;;536/23.5;;530/350,20,14,067-021-469-850-816;;120-185-171-572-797;;099-328-331-518-64X;;165-332-800-449-637;;077-755-206-358-518;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;136-172-365-845-608;;038-819-987-457-345;;051-092-210-790-698;;157-895-621-716-196;;102-583-874-731-812;;026-074-902-787-187,11738041;;10.1016/s0969-2126(01)00679-7;;10364240;;10.1074/jbc.274.25.17934;;10.1016/0014-5793(95)00434-b;;7774712;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7704571;;10.1016/s0960-9822(00)00246-3;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10.1016/0968-0004(93)90011-b;;8108862;;pmc1132210;;8424800;;10.1042/bj2890593;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1107/s0021889891004430;;10.1016/0968-0004(91)90071-3;;1652801;;2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x,"Bax et al., Structure 9:1143-1152, 2001.;;US 6,057,286, 05/2000, Harrison et al. (withdrawn);;Summers et al., The Role of Glycogen Synthase Kinase 3beta in Insulin-Stimulated Glucose Metabolism, Journal of Biological Chemistry, 274(25):17934-17940, 1999.;;GenBank accession No. AAA 84444 1996.;;Database EMBL Entry, Accession No. P49840, 1996.;;Database EMBL Entry, Accession No. P49841, 1996.;;Database EMBL Entry, Accession No. Q91627, 1996.;;Database EMBL Entry, Accession No. U31862, 1995.;;Latimer et al., Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosporylation of Transfected Tau, FEBS Letters, 365(1):42-46, 1995.;;Cross et al., The Inhibition of Glycogen Synthase Kinase-3 by Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activiated Protein Kinase Pathway in L6 Cells Between Ras and Raf, Biochemical Journal, 303(Part 1):21-26, 1994.;;Lovestone et al., Alzheimer's Disease-Like Physphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells, Current Biology, 4(12):1077-1086, 1994.;;Mulot et al., PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3beta, FEBS Letters, 349(3):359-364, 1994.;;Peifer et al., Phosphorylation of the Drosophilia Adherens Junction Protein Armadillo: Roles for Wingless Signals and Zeste-White 3 Kinase, Developmental Biology, 166(2):543-556, 1994.;;Saito et al., The Mechanism by Which Epidermal Growth Factor Inhibits Glycogen Synthase Kinase 3 in A431 Cells, Biochemical Journal, 303(Part 1):27-31, 1994.;;Mandelkow et al., Tau as a Marker for Alzheimer's Disease, TIBS, 18(12):480-483, 1993.;;Van Der Linden et al., Domain Organization of Penicillin-Binding Protein 5 from Escherichia coli Analysed by C-Terminal Truncation, Biochemical Journal, 289(Part 2):593-598, 1993.;;Welsh et al., Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor eIF-2B, Biochemical Journal, 294(Part 3):625-629, 1993.;;Jancarik et al.., Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins, J. of Applied Crystallography, 24(4):409-411, 1991.;;Woodgett, A Common Denominator Linking Glycogen Metabolism, Nuclear Oncogenes and Development, TIBS, 16(5):177-181, 1991.;;Ranty et al., Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Holoenzyme Assembly and Activity, EMBO Journal, 9:1365-1373, 1990.",EXPIRED
22,AT,T1,AT E450604 T1,016-513-992-727-178,2009-12-15,2009,AT 07022387 T,2001-07-25,US 22124200 P,2000-07-27,GSK3-POLYPEPTIDE,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/016-513-992-727-178,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,,0,0,,,,EXPIRED
23,WO,A2,WO 2002/010357 A2,094-883-437-586-019,2002-02-07,2002,US 0123539 W,2001-07-25,US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, inlcuding Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP;;HARRISON STEPHEN D;;HALL JOHN A;;CALDERON CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA SELBY ANGELICA,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/094-883-437-586-019,Patent Application,yes,0,6,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;C12N15/09;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,,0,0,,,,PATENTED
24,WO,A3,WO 2002/010357 A3,034-095-713-854-339,2003-04-03,2003,US 0123539 W,2001-07-25,US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, inlcuding Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP;;HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/034-095-713-854-339,Search Report,yes,0,0,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;C12N15/09;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,,5,2,026-074-902-787-187;;038-819-987-457-345,2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x;;pmc1132210;;8424800;;10.1042/bj2890593,"DATABASE EMBL [online] 1 October 1996 (1996-10-01), STRAUSBERG: ""KG3B_HUMAN (human GSK beta sequence)"", XP002209722, retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGETZ?-E+[SW Database accession no. P49841;;DATABASE EMBL [online] 1 November 1996 (1996-11-01), DOMINGUEZ ET AL: ""GSK-beta Xenopus"", XP002209723, Database accession no. Q91627;;DATABASE EMBL [online] 1 October 1996 (1996-10-01), HE: ""KG3A_HUMAN (human GSK alpha)"", XP002209724, Database accession no. P49840;;RANTY B ET AL: ""Truncation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Rhodospirillum rubrum affects the holoenzyme assembly and activity."", THE EMBO JOURNAL. ENGLAND MAY 1990, vol. 9, no. 5, May 1990 (1990-05-01), pages 1365 - 1373, XP001096047, ISSN: 0261-4189;;VAN DER LINDEN M P ET AL: ""Domain organization of penicillin-binding protein 5 from Escherichia coli analysed by C-terminal truncation."", THE BIOCHEMICAL JOURNAL. ENGLAND 15 JAN 1993, vol. 289 ( Pt 2), 15 January 1993 (1993-01-15), pages 593 - 598, XP002209721, ISSN: 0264-6021",PATENTED
25,US,A1,US 2003/0077798 A1,118-966-565-868-195,2003-04-24,2003,US 21141202 A,2002-07-31,US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"
   The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3 and GSK3 polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation. 
",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/118-966-565-868-195,Patent Application,yes,0,6,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;C12N15/09;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,435/194;;435/69.1;;435/320.1;;435/325;;536/23.2,0,0,,,,EXPIRED
26,PT,E,PT 1914305 E,134-628-813-882-171,2010-01-29,2010,PT 07022387 T,2001-07-25,US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/134-628-813-882-171,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
27,DE,D1,DE 60140707 D1,023-850-555-798-702,2010-01-14,2010,DE 60140707 T,2001-07-25,US 22124200 P,2000-07-27,GSK3-Polypeptide,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/023-850-555-798-702,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
28,EP,B1,EP 1319064 B1,031-576-264-296-80X,2007-11-21,2007,EP 01959230 A,2001-07-25,US 0123539 W;;US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,"NOVARTIS VACCINES AND DIAGNOSTICS, INC. (2007-01-24)",https://lens.org/031-576-264-296-80X,Granted Patent,yes,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,5,0,,,"DATABASE EMBL [Online] P49841 (Q9UL47), 1 October 1996 (1996-10-01) STRAUSBERG: ""KG3B_HUMAN (human GSK beta sequence)"" retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGET Z?-E+[SW Database accession no. P49841 XP002209722;;DATABASE EMBL [Online] 1 November 1996 (1996-11-01) DOMINGUEZ ET AL: ""GSK-beta Xenopus"" Database accession no. Q91627 XP002209723;;DATABASE EMBL [Online] 1 October 1996 (1996-10-01) HE: ""KG3A_HUMAN (human GSK alpha)"" Database accession no. P49840 XP002209724;;RANTY B ET AL: ""Truncation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Rhodospirillum rubrum affects the holoenzyme assembly and activity."" THE EMBO JOURNAL. ENGLAND MAY 1990, vol. 9, no. 5, May 1990 (1990-05), pages 1365-1373, XP001096047 ISSN: 0261-4189;;VAN DER LINDEN M P ET AL: ""Domain organization of penicillin-binding protein 5 from Escherichia coli analysed by C-terminal truncation."" THE BIOCHEMICAL JOURNAL. ENGLAND 15 JAN 1993, vol. 289 ( Pt 2), 15 January 1993 (1993-01-15), pages 593-598, XP002209721 ISSN: 0264-6021",EXPIRED
29,US,B2,US 7807430 B2,053-435-763-374-795,2010-10-05,2010,US 7454308 A,2008-03-03,US 7454308 A;;US 70472407 A;;US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/053-435-763-374-795,Granted Patent,yes,2,1,29,29,13,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,A61K35/76;;C12N9/12;;A61K38/00;;C12N15/09;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07H21/00;;C07K14/00;;C12N1/21;;C12N5/10;;C12N15/00;;C12P21/00;;C12Q1/48,435/194;;435/320.1;;435/69.1;;435/15;;435/325;;435/252.3;;530/350;;536/23.2,26,18,007-203-932-641-508;;037-327-639-081-276;;003-697-939-740-709;;013-631-335-323-382;;120-185-171-572-797;;099-328-331-518-64X;;165-332-800-449-637;;077-755-206-358-518;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;136-172-365-845-608;;038-819-987-457-345;;051-092-210-790-698;;157-895-621-716-196;;102-583-874-731-812;;026-074-902-787-187;;067-021-469-850-816,8382613;;10.1002/j.1460-2075.1993.tb05715.x;;pmc413270;;11440715;;10.1016/s0092-8674(01)00374-9;;10.1042/bj3030701;;7980435;;pmc1137602;;10.1038/nmeth.f.203;;18235435;;10364240;;10.1074/jbc.274.25.17934;;10.1016/0014-5793(95)00434-b;;7774712;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7704571;;10.1016/s0960-9822(00)00246-3;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10.1016/0968-0004(93)90011-b;;8108862;;pmc1132210;;8424800;;10.1042/bj2890593;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1107/s0021889891004430;;10.1016/0968-0004(91)90071-3;;1652801;;2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x;;11738041;;10.1016/s0969-2126(01)00679-7,"Hughes et al., The EMBO Journal 12(2):803-808, 1993.;;Dajani et al., Cell 105:721-732, 2001.;;Stambolic et al., Biochem. J. 303:701-704, 1994.;;Ishiguro et al., GenBank accession No. CAA52020, Sep. 1993.;;Chayen et al., Nature Methods 5(2):147-153, 2008.;;Summers et al., The Role of Glycogen Synthase Kinase 3beta in Insulin-Stimulated Glucose Metabolism, Journal of Biological Chemistry, 274(25):17934-17940, 1999.;;Accession No. AAA84444.1, 1996.;;Database EMBL Entry, Accession No. P49840, 1996.;;Database EMBL Entry, Accession No. P49841, 1996.;;Database EMBL Entry, Accession No. Q91627, 1996.;;Database EMBL Entry, Accession No. U31862, 1995.;;Latimer et al., Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosporylation of Transfected Tau, FEBS Letters, 365(1):42-46, 1995.;;Cross et al., The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activiated Protein Kinase Pathway in L6 Cells Between Ras and Raf, Biochemical Journal, 303(Part 1):21-26, 1994.;;Lovestone et al., Alzheimer's Disease-Like Physphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells, Current Biology, 4(12):1077-1086, 1994.;;Mulot et al., PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3beta, FEBS Letters, 349(3):359-364, 1994.;;Peifer et al., Phosphorylation of the Drosophilia Adherens Junction Protein Armadillo: Roles for Wingless Signals and Zeste-White 3 Kinase, Developmental Biology, 166(2):543-556, 1994.;;Saito et al., The Mechanism by Which Epidermal Growth Factor Inhibits Glycogen Synthase Kinase 3 in A431 Cells, Biochemical Journal, 303(Part 1):27-31, 1994.;;Mandelkow et al., Tau as a Marker for Alzheimer's Disease, TIBS, 18(12):480-483, 1993.;;Van Der Linden et al., Domain Organization of Penicillin-Binding Protein 5 from Escherichia coli Analysed by C-Terminal Truncation, Biochemical Journal, 289(Part 2):593-598, 1993.;;Welsh et al., Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor elF-2B, Biochemical Journal, 294(Part 3):625-629, 1993.;;Jancarik et al., Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins, J. of Applied Crystallography, 24(4):409-411, 1991.;;Woodgett, A Common Denominator Linking Glycogen Metabolism, Nuclear Oncogenes and Development, TIBS, 16(5):177-181, 1991.;;Ranty et al., Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Holoenzyme Assembly and Activity, EMBO Journal, 9:1365-1373, 1990.;;EMBL Accession No. L33801, May 1995.;;EMBL Accession No. S53324, 1999.;;Bax, B. et al., Structure 9:1143-1152, 2001.",EXPIRED
30,US,B2,US 7361484 B2,180-733-472-319-649,2008-04-22,2008,US 70472407 A,2007-02-08,US 70472407 A;;US 73381603 A;;US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/180-733-472-319-649,Granted Patent,yes,2,1,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;C12Q1/48;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C07K14/00;;C12N5/02;;C12N5/06;;C12N9/12;;C12N15/00;;C12P21/06;;C12P21/08;;G01N33/00;;G01N33/53;;G01N33/563,435/15;;435/69.1;;435/194;;435/325;;435/252.3;;435/7.6;;435/7.8;;435/7.92;;435/7.1;;435/320.1;;435/365;;435/6;;530/350;;530/388.1;;436/86;;436/512;;536/23.2;;536/23.5,22,14,067-021-469-850-816;;120-185-171-572-797;;099-328-331-518-64X;;165-332-800-449-637;;077-755-206-358-518;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;136-172-365-845-608;;038-819-987-457-345;;051-092-210-790-698;;157-895-621-716-196;;102-583-874-731-812;;026-074-902-787-187,11738041;;10.1016/s0969-2126(01)00679-7;;10364240;;10.1074/jbc.274.25.17934;;10.1016/0014-5793(95)00434-b;;7774712;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7704571;;10.1016/s0960-9822(00)00246-3;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10.1016/0968-0004(93)90011-b;;8108862;;pmc1132210;;8424800;;10.1042/bj2890593;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1107/s0021889891004430;;10.1016/0968-0004(91)90071-3;;1652801;;2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x,"Bax et al., Structure 9:1143-1152, Dec. 2001.;;US 6,057,286, 05/2000, Harrison et al. (withdrawn);;Summers et al., The Role of Glycogen Synthase Kinase 3beta in Insulin-Stimulated Glucose Metabolism, Journal of Biological Chemistry, 274(25):17934-17940, 1999.;;Accession No. AAA84444.1, 1996.;;Database EMBL Entry, Accession No. P49840, 1996.;;Database EMBL Entry, Accession No. P49841, 1996.;;Database EMBL Entry, Accession No. Q91627, 1996.;;Database EMBL Entry, Accession No. U31862, 1995.;;Latimer et al., Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosporylation of Transfected Tau, FEBS Letters, 365(1):42-46, 1995.;;Cross et al., The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells Between Ras and Raf, Biochemical Journal, 303(Part 1):21-26, 1994.;;Lovestone et al., Alzheimer's Disease-Like Physphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells, Current Biology, 4(12):1077-1086, 1994.;;Mulot et al., PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-Page Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3beta, FEBS Letters, 349(3):359-364, 1994.;;Peifer et al., Phosphorylation of the Drosophilia Adherens Junction Protein Armadillo: Roles for Wingless Signals and Zeste-White 3 Kinase, Developmental Biology, 166(2):543-556, 1994.;;Saito et al., The Mechanism by Which Epidermal Growth Factor Inhibits Glycogen Synthase Kinase 3 in A431 Cells, Biochemical Journal, 303(Part 1):27-31, 1994.;;Mandelkow et al., Tau as a Marker for Alzheimer's Disease, TIBS, 18(12):480-483, 1993.;;Van Der Linden et al., Domain Organization of Penicillin-Binding Protein 5 from Escherichia coli Analysed by C-Terminal Truncation, Biochemical Journal, 289(Part 2):593-598, 1993.;;Welsh et al., Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor eIF-2B, Biochemical Journal, 294(Part 3):625-629, 1993.;;Jancarik et al., Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins, J. of Applied Crystallography, 24(4):409-411, 1991.;;Woodgett, A Common Denominator Linking Glycogen Metabolism, Nuclear Oncogenes and Development, TIBS, 16(5):177-181, 1991.;;Ranty et al., Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Holoenzyme Assembly and Activity, EMBO Journal, 9:1365-1373, 1990.;;EMBL Accession No. L33801, May 1995.;;EMBL Accession No. S53324, 1999.",EXPIRED
31,PT,E,PT 1319064 E,033-307-111-951-188,2008-02-29,2008,PT 01959230 T,2001-07-25,US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/033-307-111-951-188,Granted Patent,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,0,0,,,,EXPIRED
32,EP,B1,EP 1914305 B1,058-729-145-779-328,2009-12-02,2009,EP 07022387 A,2001-07-25,EP 01959230 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",NOVARTIS VACCINES & DIAGNOSTIC,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/058-729-145-779-328,Granted Patent,yes,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N9/12;;C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00,,5,0,,,"DATABASE EMBL [Online] P49841 (Q9UL47) 1 October 1996 (1996-10-01), STRAUSBERG: ""KG3B_HUMAN (human GSK beta sequence)"" XP002209722 retrieved from HTTP://SRS6.EBI.AC.UK/SRS6BIN/CGI-BIN/WGET Z?-E+[SW Database accession no. P49841;;DATABASE EMBL [Online] 1 November 1996 (1996-11-01), DOMINGUEZ ET AL: ""GSK-beta Xenopus"" XP002209723 Database accession no. Q91627;;DATABASE EMBL [Online] 1 October 1996 (1996-10-01), HE: ""KG3A_HUMAN (human GSK alpha)"" XP002209724 Database accession no. P49840;;RANTY B ET AL: ""Truncation of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Rhodospirillum rubrum affects the holoenzyme assembly and activity."" THE EMBO JOURNAL. ENGLAND MAY 1990, vol. 9, no. 5, May 1990 (1990-05), pages 1365-1373, XP001096047 ISSN: 0261-4189;;VAN DER LINDEN M P ET AL: ""Domain organization of penicillin-binding protein 5 from Escherichia coli analysed by C-terminal truncation."" THE BIOCHEMICAL JOURNAL. ENGLAND 15 JAN 1993, vol. 289 ( Pt 2), 15 January 1993 (1993-01-15), pages 593-598, XP002209721 ISSN: 0264-6021",EXPIRED
33,AU,A,AU 2001/080812 A,096-885-933-090-049,2002-02-13,2002,AU 2001/080812 A,2001-07-25,US 22124200 P;;US 0123539 W,2000-07-27,Gsk3 polypeptides,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,,https://lens.org/096-885-933-090-049,Patent Application,no,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,,0,0,,,,PENDING
34,EP,A2,EP 1319064 A2,163-752-667-661-193,2003-06-18,2003,EP 01959230 A,2001-07-25,US 0123539 W;;US 22124200 P,2000-07-27,GSK3 POLYPEPTIDES,"The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVEN H;;MEDINA-SELBY ANGELICA,"NOVARTIS VACCINES AND DIAGNOSTICS, INC. (2007-01-24)",https://lens.org/163-752-667-661-193,Patent Application,yes,0,0,29,29,0,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,,0,0,,,,EXPIRED
35,US,B2,US 6716624 B2,090-246-984-603-212,2004-04-06,2004,US 21141202 A,2002-07-31,US 21141202 A;;US 91610901 A;;US 22124200 P,2000-07-27,GSK3 polypeptides,"
    The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3 and GSK3 polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation. 
",CHIRON CORP,HARRISON STEPHEN D;;HALL JOHN A;;CALDERON-CACIA MARIA;;ZHONG ZIYANG;;FANG ERIC Y;;COIT DORIS G;;NGUYEN STEVE H;;MEDINA-SELBY ANGELICA,,https://lens.org/090-246-984-603-212,Granted Patent,yes,2,6,29,29,11,C12N9/1205;;C12Q1/485;;C12Y207/01037;;G01N2500/00;;A61P25/28;;A61P29/00;;A61P43/00;;A61P3/10;;C12N9/1205;;G01N2500/00;;C12Q1/485;;C12Y207/01037,C12N15/09;;A61K35/76;;A61K38/00;;A61K48/00;;A61P3/10;;A61P25/28;;A61P29/00;;A61P43/00;;C12N9/12,435/320.1;;435/15;;435/194;;536/23.2;;530/350,20,13,120-185-171-572-797;;099-328-331-518-64X;;165-332-800-449-637;;077-755-206-358-518;;067-347-783-117-655;;034-002-594-044-070;;026-432-344-796-392;;136-172-365-845-608;;038-819-987-457-345;;051-092-210-790-698;;157-895-621-716-196;;102-583-874-731-812;;026-074-902-787-187,10364240;;10.1074/jbc.274.25.17934;;10.1016/0014-5793(95)00434-b;;7774712;;07945242;;7945242;;pmc1137550;;10.1042/bj3030021;;7704571;;10.1016/s0960-9822(00)00246-3;;8050597;;10.1016/0014-5793(94)00702-0;;7529201;;10.1006/dbio.1994.1336;;10.1042/bj3030027;;pmc1137551;;7945252;;10.1016/0968-0004(93)90011-b;;8108862;;pmc1132210;;8424800;;10.1042/bj2890593;;8397507;;pmc1134506;;10.1042/bj2940625;;10.1107/s0021889891004430;;10.1016/0968-0004(91)90071-3;;1652801;;2109693;;pmc551821;;10.1002/j.1460-2075.1990.tb08251.x,"Stambolic et al., EMBL accession No. L33801, May 1995.*;;Stambolic et al., PIR accession No. S53324, 1999.*;;US 6,057,286, 5/2000, Harrison et al. (withdrawn);;Summers et al., The Role of Glycogen Synthase Kinase 3beta Insulin-Stimulated Glucose Metabolism, Journal of Biological Chemistry, 274(25): 17934-17940, 1999.;;Database EMBL Entry, Accession No. Q91627, Nov. 1, 1996.;;Database EMBL Entry, Accession No. P49840, Oct. 1, 1996.;;Database EMBL Entry, Accession No. P49841, Oct. 1, 1996.;;Database EMBL Entry, Accession No. U31862, Oct. 1, 1995.;;Latimer et al., Stimulation of MAP kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosporylation of Transfected Tau, FEBS Letters, 365(1): 42-46, 1995.;;Cross et al., The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell line L6 is Blocked by Wortmannin, but not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 cells Between Ras and Raf, Biochemical Journal,303 (Part 1): 21-26, 1994.;;Lovestone et al., Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells, Current Biology, 4(12): 1077-1086, 1994.;;Mulot et al., PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-PAGE which can be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3 beta, FEBS Letters, 349(3): 359-364, 1994.;;Peifer et al., Phosphorylation of the Drosophila Adherens Junction Protein Armadillo; Roles for Wingless Signals and Zeste-White 3 Kinase, Developmental Biology 166(2): 543-556, 1994.;;Saito et al., ""The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells,"" Biochemical Journal 303(Part 1): 27-31, 1994.;;Mandelkow and Mandelkow, Tau as a Marker for Alzheimer's Disease. TIBS, 18(12): 480-483, 1993.;;Van Der Linden et al., Domain Organization of Penicillin-Binding Protein 5 from Escherichia Coli Analysed by C-Terminal Truncation, Biochemical Journal, 289(Part 2): 593-598, 1993.;;Welsh and Proud, Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor elF-2B, Biochemical Journal, 294(Part 3): 625-629, 1993.;;Jancarik and Kim, Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins, J. of Applied Crystallography, 24(4): 409-411, 1991.;;Woodgett, A Common Denominator Linking Glycogen Metabolism, Nuclear Oncongenes and Development, TIBS, 16(5): 177-181, 1991.;;Ranty et al., Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Rhodospirillum Rubrum Affects the Holoenzyme Assembly and Activity, EMBO Journal, 9: 1365-1373, 1990.",EXPIRED
36,US,A1,US 2022/0259523 A1,072-340-789-873-653,2022-08-18,2022,US 202217673191 A,2022-02-16,US 202217673191 A;;US 202163150812 P,2021-02-18,STABLE ACTIVATED PEROXIDE SANITIZING LIQUID COMPOSITIONS WITHOUT ADDED PHOSPHOROUS COMPOUNDS OR CATIONIC SURFACTANTS,"Peroxide treatment compositions for use in laundry capable of providing sanitization through the wash e.g., for use with a detergent, where a peroxide activator is stabilized without the presence of phosphorus-containing compounds (e.g., phosphorus-containing stabilizers), through use of a nonionic surfactant (e.g., alkoxylated alcohol) with a cloud point above 45° C. Use of a single nonionic surfactant, or a surfactant package that may include a small fraction (e.g., less than 0.5%) of sodium lauryl sulfate or another anionic surfactant has been found to be surprisingly effective at stabilizing the peroxide/activator combination, even where water content may be 85% or greater. The composition can have a pH of 5 or less (e.g., 3 to 4). The composition may be free of other anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, magnesium salts, borates and boric acid, hydroxides, chelating agents, various amine oxides, ethoxylated amines, and the like.",CLOROX CO,FALK NANCY A;;MUI TIMOTHY P;;RUMBERGER EVAN;;GUO XUANRONG;;FRAUSTO FANNY;;CAPRACOTTA MICHAEL;;PENA CALDERON DENNYS D;;SCHEUING DAVID R;;DENTINGER CLAIRE E J;;GROSS STEPHEN F;;NORBERG NICHOLAS S;;THAMANNA SHAKERA,THE CLOROX COMPANY (2021-08-02);;BASF CORPORATION (2021-08-09),https://lens.org/072-340-789-873-653,Patent Application,yes,11,0,2,2,0,C11D3/0047;;C11D3/222;;C11D3/48;;C11D3/3947;;C11D1/72;;C11D1/83;;C11D3/3937;;C11D3/0047;;C11D17/0008;;C11D3/3409;;C11D3/222;;C11D1/722,C11D3/39;;C11D1/722;;C11D3/00;;C11D3/22;;C11D3/34;;C11D17/00,,0,0,,,,PENDING
37,WO,A1,WO 2022/178121 A1,117-748-687-939-287,2022-08-25,2022,US 2022/0016787 W,2022-02-17,US 202163150812 P;;US 202217673191 A,2021-02-18,STABLE ACTIVATED PEROXIDE SANITIZING LIQUID COMPOSITIONS WITHOUT ADDED PHOSPHORUS COMPOUNDS OR CATIONIC SURFACTANTS,"Peroxide treatment compositions for use in laundry capable of providing sanitization through the wash e.g., for use with a detergent, where a peroxide activator is stabilized without the presence of phosphorus-containing compounds (e.g., phosphorus-containing stabilizers), through use of a nonionic surfactant (e.g.,alkoxylated alcohol) with a cloud point above 45°C. Use of a single nonionic surfactant, or a surfactant package that may include a small fraction (e.g., less than 0.5%) of sodium lauryl sulfate or another anionic surfactant has been found to be surprisingly effective at stabilizing the peroxide/activator combination, even where water content may be 85% or greater. The composition can have a pH of 5 or less (e.g., 3 to 4). The composition may be free of other anionic surfactants, cationic surfactants, zwitterionic surfactants, amphoteric surfactants, magnesium salts, borates and boric acid, hydroxides, chelating agents, various amine oxides, ethoxylated amines, and the like.",CLOROX CO,FALK NANCY A;;MUI TIMOTHY P;;RUMBERGER EVAN;;GUO XUANRONG;;FRAUSTO FANNY;;PENA CALDERON DENNYS D;;SCHEUING DAVID R;;DENTINGER CLAIRE E J;;NORBERG NICHOLAS S;;CAPRACOTTA MICHAEL;;GROSS STEPHEN F;;THAMANNA SHAKERA,,https://lens.org/117-748-687-939-287,Patent Application,yes,7,0,2,2,0,C11D3/0047;;C11D3/222;;C11D3/48;;C11D3/3947;;C11D1/72;;C11D1/83;;C11D3/3937;;C11D3/0047;;C11D17/0008;;C11D3/3409;;C11D3/222;;C11D1/722,A01N59/16;;D06M15/71,,0,0,,,,PENDING
